A new financial analysis of the HIV drug market highlights the potential reshuffling of market positions as the patents of AIDS drugs expire (money.cnn.com, 11/19).
It is estimated that the $8 billion HIV drug market will expand by approximately 50 percent by 2016, says analyst Mansi Shah of research company Datamonitor.
With two thirds of current HIV drug patents expiring in the next 10 years, more and more companies are expected to challenge top drugmakers. In addition, experts attribute the booming market to advanced HIV medications, which will keep those living with the virus—and the drug market—alive and well for years to come.
“HIV patients live much longer,” says Jason Zhang, an analyst for BMO Capital Markets. “They have the disease for life, and that’s why the market is growing.”
SugarandSpice43
